Sanofi Just Gave Myeloma Patients Their Hours Back
The FDA approved a wearable on-body injector version of Sanofi's myeloma drug Sarclisa, making it the first cancer therapy in the U.S. delivered this way. It won't dethrone J&J's Darzalex overnight, but it just erased one of the biggest reasons doctors defaulted to the competition.
Picture this: you're a multiple myeloma patient, and every two weeks you spend hours tethered to an IV pole in a clinic. That's your Tuesday. Every Tuesday. For years.
Now picture a small device stuck to your arm that does the same job in minutes, while you scroll your phone or chat with a nurse. That's the promise of subcutaneous Sarclisa.
Sanofi's subcutaneous Sarclisa Escena, a wearable on-body injector (OBI) version of the company's CD38-targeting antibody isatuximab, is currently under FDA review, with a PDUFA target action date of July 23, 2026. It covers all four existing multiple myeloma indications where IV Sarclisa is already approved, spanning both newly diagnosed and relapsed patients. And it would make Sarclisa Escena the first cancer therapy in the U.S. delivered via an on-body injector.
That last part matters more than it sounds.
Why a New Way to Deliver the Same Drug Is Actually a Big Deal
Let's be clear: subcutaneous Sarclisa is the same molecule as IV Sarclisa. Same target (CD38, a protein found on myeloma cells). Same mechanism. Sanofi didn't reinvent the drug. They reinvented the experience of taking it.
And in cancer treatment, experience isn't a luxury; it's a retention strategy. Patients who dread their infusion days are patients who consider stopping treatment. Patients who lose entire workdays to chair time are patients bearing invisible economic costs that never show up in a clinical trial.
The numbers on this are striking. In studies of subcutaneous versus IV delivery in myeloma, clinic time dropped dramatically per visit. Actual drug administration time? That fell by over 90%, from several hours to minutes with subcutaneous Sarclisa. Only 22% of patients found the subcutaneous process burdensome, compared with 44% for IV.
Over the course of two years of treatment, that convenience gap adds up to hundreds of hours returned to patients' lives.
The Clinical Case: Does It Actually Work as Well?
Convenience means nothing if the drug doesn't perform. So Sanofi ran the Phase 3 trial, testing subcutaneous Sarclisa (delivered via the on-body injector) against the IV version, both combined with pomalidomide and dexamethasone in relapsed or refractory myeloma patients.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
IRAKLIA
The trial had two co-primary endpoints: objective response rate (ORR, the percentage of patients whose tumors shrank meaningfully) and drug trough levels at steady state (basically, how much drug stays in your blood between doses). On both counts, SC was non-inferior to IV.
Response rates were virtually identical: 71.1% for subcutaneous versus 70.5% for IV.
Pharmacokinetics told a similar story. Trough drug levels with subcutaneous delivery were about 30% higher than IV (421 vs. 302 µg/mL), meaning patients actually got slightly more sustained drug exposure. More drug hanging around longer is generally a good thing when you're fighting cancer.
Fewer Needles, Fewer Reactions
Beyond convenience, the safety profile had one standout finding. Systemic infusion reactions (the chills, fever, and nausea that can accompany IV antibody infusions) occurred in just 1.5% of subcutaneous patients, compared to 25% of IV patients. That's a 94% relative reduction.
Local injection-site reactions with the on-body device were rare: only 0.4% of injections caused any reaction, and nearly all were mild, Grade 1 events. The device itself performed well too, with 99.9% of OBI injections successfully delivered.
The overall safety profile (serious infections, blood count issues, and the other risks that come with myeloma treatment) looked comparable between routes. No new safety signals emerged.
The Elephant in the Infusion Room: Darzalex
You can't talk about Sarclisa without talking about Johnson & Johnson's Darzalex (daratumumab), the other CD38 antibody in myeloma and, frankly, the Goliath of this market.
Darzalex pulled in roughly $12 billion in 2024 sales. Sarclisa managed about €588 million (approximately $700 million) in the same year. That's not a rivalry; that's a weight class difference.
And here's the kicker: Darzalex already has a subcutaneous version. Darzalex Faspro has been on the market since 2020 and now accounts for an estimated 73% of new daratumumab prescriptions in the U.S. J&J figured out years ago that convenience sells.
So Sanofi is late to this particular party. The subcutaneous approval doesn't suddenly make Sarclisa a Darzalex killer. What it does is remove Darzalex's convenience moat. Until now, if a doctor wanted to spare their patient hours in the infusion chair, Darzalex Faspro was the obvious choice. That default just got a lot less automatic.
Sarclisa's on-body injector also introduces a wrinkle that Darzalex Faspro doesn't have. The OBI is hands-free: a nurse applies the device, and the patient wears it while the drug delivers itself. That frees up nursing time in busy infusion centers, which is a practical selling point for clinics operating at capacity.
Follow the Money
Sarclisa has been growing fast, even before this anticipated approval. In 2024, sales reached approximately €588 million (around $700 million), reflecting strong growth. In 2025, the franchise grew another 28.5%. Sanofi CEO Paul Hudson has publicly stated his expectation that Sarclisa will cross the $1 billion threshold soon, powered by first-line use in newly diagnosed patients and now the subcutaneous formulation.
The anti-CD38 antibody market in myeloma is expected to reach €16 billion by the end of the decade, according to Sanofi's own estimates. Even capturing a modest additional slice of that pie would be meaningful. Sarclisa doesn't need to dethrone Darzalex; it just needs to keep growing its share in a market that's expanding for everyone.
Analysts seem to agree with that framing. Wall Street is treating the SC filing as a franchise-strengthening move rather than a transformational event. It protects Sarclisa from becoming the "IV-only" option in a world that's moving toward convenience, and it gives sales reps a genuine talking point in competitive accounts. Some equity models flag Sanofi as trading well below estimated fair value, with the oncology portfolio (Sarclisa included) cited as a catalyst for potential multiple expansion.
Sanofi's Bigger Myeloma Playbook
The subcutaneous filing is just one piece of Sanofi's myeloma strategy. The company has been methodically expanding Sarclisa's footprint across the treatment landscape, pushing it into earlier lines of therapy where patient volumes are larger.
The IMROZ trial led to approvals in transplant-ineligible newly diagnosed myeloma, a major segment. Two German trials (GMMG-HD7 and GMMG-HD8) are testing Sarclisa in transplant-eligible newly diagnosed patients, which could unlock filings around 2026 or beyond. And the ISASOCUT study is evaluating the OBI formulation specifically in frontline treatment combinations.
The pattern is clear: embed Sarclisa into every major treatment setting, then make it as easy as possible to administer. Sarclisa is now approved in nearly 60 countries across four indications.
Why This Matters Beyond Myeloma
Zoom out, and subcutaneous Sarclisa Escena represents something larger than one drug in one cancer. It's a proof of concept for on-body injector technology in oncology. If a wearable device can safely and effectively deliver a complex monoclonal antibody for myeloma, the same platform could potentially work for other cancer drugs that currently chain patients to infusion centers.
The myeloma market is often where new delivery paradigms get tested first, partly because patients are on treatment for years and the cumulative burden of IV infusions is enormous. Darzalex Faspro proved the subcutaneous concept. Sarclisa Escena just raised the bar with hands-free delivery.
For the roughly 35,000 Americans diagnosed with multiple myeloma each year, this approval won't change what drug they take. But it might change how their Tuesdays feel. And sometimes, that's the kind of innovation that matters most.
Clinical & Regulatory
5 min read
Germany Just Made It Harder to Sell Drugs in Europe's Biggest Market
Germany's parliament just passed sweeping drug pricing reforms that squeeze pharma margins from every angle. The ripple effects could reshape how medicines are priced across all of Europe.
